Displaying drugs 1651 - 1675 of 2779 in total
| Name | Weight | Structure | Description | Categories |
|---|---|---|---|---|
| Gadopiclenol | 970.1 C35H54GdN7O15 |  | A gadolinium-based contrast agent (GBCA) used with contrasted magnetic resonance imaging (MRI) to detect and visualize lesions and abnormal vascularity. | Contrast Media / Diagnostic Uses of Chemicals / Gadolinium-based Contrast Agent / Lanthanoid Series Elements / Magnetic Resonance Contrast Activity / Magnetic Resonance Imaging Contrast Media / Paramagnetic Contrast Agent / Paramagnetic Contrast Media |
| Gadopentetic acid | 547.58 C14H20GdN3O10 |  | A gadolinium compound used as a contrast agent in MRIs. | Paramagnetic Contrast Media |
| Gadolinium | 157.25 Gd |  | Gadolinium is under investigation in Hypertension, ACUTE KIDNEY INJURY, and Chronic Kidney Disease. Gadolinium has been investigated for the basic science of CAD, Multiple Sclerosis, and Coronary Artery Disease. | Anti-Inflammatory Agents / Contrast Media / Lanthanoid Series Elements |
| Gadofosveset trisodium | 1003.85 C33H38GdN3Na5O14P |  | An intravenous contrast agent used during magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with peripheral vascular disease. | Paramagnetic Contrast Media |
| Gadodiamide | 573.66 C16H26GdN5O8 |  | A gadolinium-based contrast agent (GBCA) used with contrasted magnetic resonance imaging (MRI) to detect and visualize lesions and abnormal vascularity. | Paramagnetic Contrast Media |
| Gadobutrol | 604.72 C18H31GdN4O9 |  | A gadolinium-based contrast agent (GBCA) used with contrasted magnetic resonance imaging (MRI) to detect and visualize lesions and abnormal vascularity. | Paramagnetic Contrast Media |
| Gadobenic acid | 667.73 C22H28GdN3O11 |  | A gadolinium-based contrast agent (GBCA) used with contrasted magnetic resonance imaging (MRI) to detect and visualize lesions and abnormal vascularity. | Paramagnetic Contrast Media |
| Gabapentin enacarbil | 329.393 C16H27NO6 |  | A gabapentin prodrug used to treat Restless Legs Syndrome (RLS) and postherpetic neuralgia (PHN). | Anti-epileptic Agent |
| Gabapentin | 171.2368 C9H17NO2 |  | An anticonvulsant medication used in the management of peripheral neuropathic pains, postherpetic neuralgia, and partial-onset seizures. | Gabapentinoids |
| Futibatinib | 418.457 C22H22N6O3 |  | A kinase inhibitor used to treat intrahepatic cholangiocarcinoma in previously treated adults. | Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors |
| Fusidic acid | 516.7092 C31H48O6 |  | A topical antibacterial agent used to prevent and treat mild to moderate skin infections caused by susceptible bacteria. | Medicated Dressings With Antiinfectives / Steroid Antibacterials |
| Fusafungine | 639.8204 C33H57N3O9 |  | Fusafungine is an antibiotic from Fusarium lateririum, and is used for the treatment of respiratory infections. | Anti-Bacterial Agents |
| Fursultiamine | 398.543 C17H26N4O3S2 |  | Compound used for therapy of thiamine deficiency. It has also been suggested for several non-deficiency disorders but has not yet proven useful. Fursultiamine is a vitamin B1 derivative. | Vitamin B Complex |
| Furosemide | 330.744 C12H11ClN2O5S |  | A loop diuretic used to treat hypertension and edema in congestive heart failure, liver cirrhosis, renal disease, and hypertension. | High-Ceiling Diuretics and Potassium-Sparing Agents / Sulfonamides |
| Fulvestrant | 606.78 C32H47F5O3S |  | An estrogen receptor antagonist used to treat HR+ breast cancer that may also be HER2-. | Anti-Estrogens |
| Fruquintinib | 393.399 C21H19N3O5 |  | A VEGF receptor inhibitor used to treat metastatic colorectal cancer. | Cytochrome P-450 CYP2C19 Substrates / Cytochrome P-450 CYP2C8 Substrates / Cytochrome P-450 CYP2C9 Substrates / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 CYP3A5 Substrates / Cytochrome P-450 CYP3A7 Substrates / Cytochrome P-450 Substrates / Heterocyclic Compounds, Fused-Ring |
| Fructose | 180.1559 C6H12O6 |  | Not Available | Carbohydrates |
| Frovatriptan | 243.3043 C14H17N3O |  | A 5-HT1B/1D receptor agonist used to treat migraines. | Selective Serotonin 5-HT1 Receptor Agonists / Serotonin Receptor Agonists |
| Framycetin | 614.6437 C23H46N6O13 |  | An aminoglycoside antibiotic used in various formulations and combinations with other agents to treat hemorrhoids, eye and ear infections, and to reduce nasal carriage of staphylococcus. | Medicated Dressings With Antiinfectives |
| Fostemsavir | 583.498 C25H26N7O8P |  | An antiretroviral HIV-1 attachment inhibitor targeted against the gp120 subunit within the HIV-1 gp160 envelope glycoprotein. | Anti-HIV Agents / HIV Fusion Inhibitors |
| Fostamatinib | 580.4595 C23H26FN6O9P |  | A spleen tyrosine kinase inhibitor used to treat chronic immune thrombocytopenia after attempting one other treatment. | Amines / BCRP/ABCG2 Inhibitors / Blood and Blood Forming Organs / Cytochrome P-450 CYP3A Inhibitors / Cytochrome P-450 CYP3A Substrates / Cytochrome P-450 CYP3A4 Inhibitors / Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) / Cytochrome P-450 CYP3A4 Substrates / Cytochrome P-450 Enzyme Inhibitors / Cytochrome P-450 Substrates / Experimental Unapproved Treatments for COVID-19 / Hemostatics / Kinase Inhibitor / Oxazines / Phosphodiesterase 5 Inhibitors / Pyridines / Tyrosine Kinase Inhibitors / UGT1A1 Inhibitors / UGT1A9 Substrates / Vasodilating Agents |
| Fospropofol | 288.2766 C13H21O5P |  | A sedative-hypnotic agent indicated for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures. | Anesthetics, General / Hypnotics and Sedatives |
| Fosphenytoin | 362.2739 C16H15N2O6P |  | An antiepileptic agent used for the management of generalized convulsive status epilepticus and prevention and treatment of seizures occurring during neurosurgery. | Anti-epileptic Agent / Hydantoins / Prodrugs / Sodium Channel Blockers |
| Fosnetupitant | 688.608 C31H35F6N4O5P |  | A medication used in combination with others to prevent chemotherapy associated nausea and vomiting. | Substance P/Neurokinin-1 Receptor Antagonist |
| Foslevodopa | 277.169 C9H12NO7P |  | Foslevodopa is under investigation in clinical trial NCT04750226 (Study to Assess Adverse Events and Change in Disease Activity of 24-hour Continuous Subcutaneous Infusion of ABBV-951 in Adult Participants With Advanced... | Dopa and Dopa Derivatives |
Displaying drugs 1651 - 1675 of 2779 in total